Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer
Junjie Li, Tong Liu, Ke-Da Yu, Huawei Yang, Zhen Huang, Yi Zeng, Peng Ji, Xiaoke Hou, Chunping Liu, Yiwen Zhang, Nanlin Li, Zhong Ouyang, Xiaobo Wu, Xiaorong Bai, Yanxiang Guo, Guohui Han, Shien Cui, Zhijun Zhu, Yu Zhang, Xiaobo Hu, Xiaopeng Ma, Peifen Fu, Jinhai Zhu, Yuan Dong, Tao Wu, Hongyan Jia, · 2026
Read Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer by Junjie Li, Tong Liu, Ke-Da Yu, Huawei Yang, Zhen Huang, Yi Zeng, Peng Ji, Xiaoke Hou, Chunping Liu, Yiwen Zhang, Nanlin Li, Zhong Ouyang, Xiaobo Wu, Xiaorong Bai, Yanxiang Guo, Guohui Han, Shien Cui, Zhijun Zhu, Yu Zhang, Xiaobo Hu, Xiaopeng Ma, Peifen Fu, Jinhai Zhu, Yuan Dong, Tao Wu, Hongyan Jia, (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13543038.txt.
Description
For breast cancers driven by the ERBB2 growth switch, treatment before surgery usually pairs chemotherapy with two antibodies. Junjie Li and co-authors test a challenger pairing in a 2026 phase 3 trial across sixty-one hospitals in China. One drug, anbenitamab, grabs the switch at two points at once and clusters it hard. The other, HB1801, is a solvent-free, albumin-bound form of the chemotherapy docetaxel.
Patients with stage two or three disease were randomized evenly between the new pairing and standard care for six cycles before surgery. The trial asks whether the double-grip antibody plus the reformulated chemotherapy clears more cancer from the breast without adding toxicity. Enrollment ran through 2025 with analysis in early 2026. The paper reports the trial's design and its primary comparison, a registrational test of a homegrown regimen.
Catalog record
| CREATOR | Junjie Li, Tong Liu, Ke-Da Yu, Huawei Yang, Zhen Huang, Yi Zeng, Peng Ji, Xiaoke Hou, Chunping Liu, Yiwen Zhang, Nanlin Li, Zhong Ouyang, Xiaobo Wu, Xiaorong Bai, Yanxiang Guo, Guohui Han, Shien Cui, Zhijun Zhu, Yu Zhang, Xiaobo Hu, Xiaopeng Ma, Peifen Fu, Jinhai Zhu, Yuan Dong, Tao Wu, Hongyan Jia, |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |